What type of study is this?

This is a Meta-Analysis study (also classified as: Systematic Review).

December 8, 2025Blood

CPX-351 versus venetoclax plus hypomethylating agents for newly diagnosed acute myeloid leukemia: A systematic review and meta-analysis

View Full Paper

Ask AI

Bookmark

CPX-351 did not show superior complete remission rates compared to venetoclax plus hypomethylating agents in acute myeloid leukemia treatment.
The pooled hazard ratio for overall survival favored CPX-351 but was not statistically significant, indicating further investigation is needed.
Observational and randomized controlled trials on 1,807 newly diagnosed patients were systematically reviewed to evaluate treatment effectiveness.
Findings highlight the need for prospective studies to identify the best therapy for older adults with acute myeloid leukemia.

Authors

No takes yet. Share an insight, caveat, or question.

Systematic review and meta-analysis reveal venetoclax plus hypomethylating agents may not outperform CPX-351 in acute myeloid leukemia treatment.

Miyashita et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

Systematic review and meta-analysis reveal venetoclax plus hypomethylating agents may not outperform CPX-351 in acute myeloid leukemia treatment.